Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Attovia Therapeutics reported a third-quarter 2026 net loss of $22.3 million and approximately $395.9 million in cash, cash equivalents, and marketable securities as of September 30, which it expects to fund operations into 2030. The company announced positive topline 12-week Phase 1b results for ATTO-1310, its candidate for chronic pruritus and high-itch atopic dermatitis. Attovia plans to start global Phase 2 trials for ATTO-1310 in the first half of 2027 and expects to begin Phase 1 trials for ATTO-2306 and ATTO-1091 during the same period.